Vaxil Granted First US Patent for Its Cancer Immunotherapy Antibody Platform – Marketwired (press release)
|
Vaxil Granted First US Patent for Its Cancer Immunotherapy Antibody Platform
Marketwired (press release) NESS-ZIONA, ISRAEL–(Marketwired – March 01, 2018) – VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has successfully obtained a U.S. Patent for its Signal … |
